Kimberly is Founder and CEO of KKH Advisors, a life sciences and digital health advisory firm. She was previously Senior Director at FTI Consulting, Life Sciences and Healthcare, where she advised a broad range of clients from Fortune 500 to early-stage development companies on business transformation, corporate and executive positioning, crisis and issues management, and financial communications.
Prior to FTI Consulting, she was Global Editor at BioPharm Insight, a business intelligence service launched by the Financial Times Group. Starting as an M&A reporter in Hong Kong covering the pharmaceutical sector at Mergermarket, she was quickly sector lead before transferring to New York to launch Biopharm Insight in 2007.
Kimberly is a frequent guest speaker at healthcare investor conferences, including the Prix Galien Forum, Biotech Showcase, FierceBiotech Drug Development Forum, Davis Polk IPO Seminars, New York Health Forun, NYVCA Summit, and others.
In 2011, based on her extensive coverage of Alzheimer's disease, she was nominated by the Alzheimer's Association as a National Press Foundation Fellow. She is also recipient of the National Press Foundation and UN Foundation Global Vaccines Press Fellowship 2012, the Association of Health Care Journalists 2012 Fellowship Award (New York State Health Foundation), and the National Press Foundation 2012 Fellowship on Cancer Issues in Washington, D.C.
Kimberly is a Board Member for the Galien Foundation, and an advisor to two Stanford Medical digital health startups, Savonix and Univfy. She is also an advisor for Springboard Enterprise's Tech Innovation Hub, and a digital health advisor for Array Ventures, a SF-based tech VC fund. She is on the editorial board for the World Korean Medical Journal, and is also a mentor for Health 2.0's TECHquality program, which fosters diversity in digital health. She has a B.A in Psychology from New York University. She is fluent in Cantonese, Shanghainese, and Mandarin.